Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial (ECTRIMS 2025) - Sep 25, 2025 - Abstract #P918; 157; "Introduction: Privosegtor (OCS-05), a peptoid small molecule, has shown neuroprotective activity in several experimental animal models and is being studied as a treatment for acute optic neuritis (AON)... This phase 2 multi-center, randomized, double-masked, placebo-controlled study (ACUITY) tested privosegtor (2 or 3 mg/kg IV daily for 5 days) as add-on to standard of care (methylprednisolone IV) in patients with AON of <12 days duration, excluding AQP4+ patients... Privosegtor as add-on to standard of care was well-tolerated in AON and showed reduced retina damage suggesting neuroaxonal preservation, and significant improvement in visual function by end of follow-up. Disclousure of interest: Céline Louapre and Sophie Bonnin contributed equally. Céline Louapre has received speaker or consultancy fees from Biogen, Sanofi, Novartis and Merck, not related to the present study, and is consultant for Oculis SA."
Clinical • Late-breaking abstract • CNS Disorders • Movement Disorders • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis • Parkinson's Disease
|
|
Céline Louapre 1 , Sophie Bonnin 2 , Louise-Laure Mariani 1 , 3 , Mikael Cohen 4 , Caroline Froment 5 , Mark Kupersmith 6 , Leonard Levin 7 , Sabri Markabi 8 , Caroline Papeix 9 , Valérie Touitou 10 , Sebastian Wolf 11 , Pablo Villoslada 12
|